Vin Gupta, Chief Medical Officer at Amazon Pharmacy, speaks during Amazon’s “Delivering the Future” event at the company’s BFI1 Fulfillment Center, Robotics Research and Development Hub in Sumner, Washington on October 18, 2023.
Jason Redmond | Afp | Getty Images
Amazon has lost the chief medical officer of its pharmacy division after five years at the company.
Dr. Vin Gupta, who most recently served as the medical chief of Amazon Pharmacy, joined Amazon in 2020 as the company was in the early stages of a multi-year effort to build out a health-care business.
Gupta has joined Manatt, Phelps & Phillips, LLP, a professional services firm, as a managing director to lead a portfolio dedicated to health innovation, according to a release. Amazon didn’t immediately name a successor for Gupta, whose LinkedIn profile says he left last month.
“We are grateful to Dr. Gupta for all of his contributions to Amazon Health Services and wish him the best in his next endeavor,” an Amazon spokesperson told CNBC in a statement Wednesday.
Gupta said in an emailed statement that Manatt, like Amazon, “is deeply focused on scaled impact to address problems which matter to patients nationwide,” including care access and the use of artificial intelligence “at the point of need.”
For Amazon CEO Andy Jassy, Gupta’s exit marks another high-profile departure across the health businesses. Earlier this month, One Medical CEO Trent Green announced he would step down from leading the primary care chain in April, after less than two years in the role. Amazon acquired One Medical for $3.9 billion in 2023, five years after snapping up online pharmacy PillPack for about $750 million.
In addition to his role within the pharmacy business, Gupta held several other positions over the course of his five years at the company, including Covid response lead and chief medical officer of new products in Amazon’s devices and services unit.
Gupta joined Amazon months before it launched its pharmacy offering, a service that was born out PillPack deal in 2018. In his role as chief medical officer, Gupta helped roll out a prescription perk for U.S. Prime members called RxPass and expanded its program for medication delivery by drones.
Gupta was also involved with a moonshot incubator at Amazon called Grand Challenge, which launched under founder Jeff Bezos as a way to develop experimental businesses, including health-care initiatives.
Disclosure: Dr. Vin Gupta contributes to NBC News as a medical analyst.
Elon Musk’s Twitter profile displayed on a computer screen and Twitter logo displayed on a phone screen are seen in this illustration photo taken in Krakow, Poland on April 9, 2022.
Jakub Porzycki | Nurphoto | Getty Images
A proposed class-action lawsuit against Elon Musk and his family office Excession can proceed in federal court, a judge ruled Friday, after the tech centi-billionaire sought to have the case dismissed.
The case is Rasella v. Musk (Case No. 1:22-cv-03026-ALC-GWG) in the Southern District of New York.
The lawsuit was brought by former Twitter shareholders who allege they lost money when the Tesla and SpaceX CEO was amassing a stake in the social network, but failed to disclose his purchases within a legally-mandated time frame.
The Oklahoma Firefighters Pension and Retirement System and other plaintiffs in the suit complained that they had sold shares of then publicly-traded Twitter at “artificially deflated prices,” while Musk obscured his own interest and stake in the company.
Elon Musk and Jared Birchall did not immediately respond to a request for comment.
Musk’s attorneys have argued that while his disclosure was filed after an SEC-mandated deadline, this was merely an error and that the tech magnate did not commit nor intend securities fraud.
In his opinion, Judge Andrew L. Carter in the Southern District of New York wrote that the court agreed with plaintiffs that Musk’s failure to disclose he was snapping up shares of Twitter sent a “false pricing signal to the market.”
In his 43-page opinion, the judge also noted that Musk had posted a tweet on March 26, 2022 indicating he was thinking about buying a different social network, not Twitter, although he had already amassed millions of shares in Twitter as of March 25, 2022.
He wrote, it was “reasonable” to read Musk’s tweet “as a statement meant to misdirect the public to think that buying Twitter was just a fantasy.” The judge also wrote that, “it is more likely than not that Musk issued a material misleading representation,” with those tweets.
Musk ultimately bid on and led a leveraged buyout of Twitter in 2022 in a deal worth about $44 billion. He made sweeping changes to the business, the social platform and later renamed it X.
As previously reported, the Securities and Exchange Commission filed a similar lawsuit against Musk over alleged failure to properly disclose purchases of Twitter stock in 2022 before he took over the company.
On Friday, Musk said another one of his ventures, xAI, was merging with the social network in an all-stock transaction, valuing the artificial intelligence business at $80 billion and the social media business at $33 billion.
Elon Musk said on Friday that his startup xAI has merged with X, his social network, in an all-stock transaction that values the artificial intelligence company at $80 billion and the social media company at $33 billion.
“xAI and X’s futures are intertwined,” Musk, the world’s richest person, wrote in a post on X. “Today, we officially take the step to combine the data, models, compute, distribution and talent.”
He added that the merger would, “unlock immense potential by blending xAI’s advanced AI capability and expertise with X’s massive reach.” The purchase price, he said, was $45 billion less $12 billion in debt.
Because both companies are privately held and controlled by Musk, the transaction likely amounts to a stock swap, with X investors getting paid out in xAI shares. The companies have a number of mutual investors, including venture firms Andreessen Horowitz and Sequoia Capital, as well as Fidelity Management, Vy Capital and Saudi Arabia’s Kingdom Holding Co.
Musk, who’s also CEO of Tesla and SpaceX, acquired Twitter in a deal valued at around $44 billion in late 2022, implementing massive cost cuts and soon renaming it X. Linda Yaccarino, who Musk hired as CEO of X, wrote in a post after Friday’s announcement, “The future could not be brighter.”
Musk launched xAI less than two years ago with a stated goal to “understand the true nature of the universe.” The startup has been trying to compete directly with OpenAI, the richly valued AI startup that Musk co-founded in 2015 as a non-profit research lab. He later left OpenAI and has recently been involved in a public relations and legal spat with the company and CEO Sam Altman over the direction that it’s taken.
At xAI, Musk’s team has been developing large language models and AI software products, taking on offerings from OpenAI as well as Google, Microsoft, Meta and others. X and xAI have already been intertwined, with xAI’s Grok chatbot available to users of the social media app.
In June, xAI announced it would build a supercomputer in Memphis, Tennessee, to train Grok. And in September, Musk revealed part of the Memphis supercomputer, now known as Colossus, was already online.
Environmental and public health advocates have raised concerns about the breakneck speed of development in Memphis, citing a lack of community input and oversight. The facility is powered by natural gas burning turbines and xAI plans to expand and build a graywater treatment plant nearby as well.
Investors valued xAI at around $50 billion in a financing round last year. Bloomberg reported last month that the company was in talks to raise funds at a $75 billion valuation. OpenAI was closed to wrapping up a round in February at a $260 billion, while generative AI startup Anthropic was valued at $61.5 billion in a deal that closed this month.
In addition to running Tesla, SpaceX and xAI and overseeing X, Musk has spent much of his time this year in Washington, D.C., as a central figure in President Donald Trump’s second administration.
After contributing close to $300 million to help Trump and other Republican candidates and causes in the 2024 campaign, Musk was put in charge of the newly formed Department of Government Efficiency (DOGE), which is eliminating government expenses and getting rid of regulations. It’s a position that puts Musk in position to make changes in ways that benefit his various businesses.
This isn’t the first time Musk has merged two of his entities.
In 2016, Tesla acquired SolarCity for $2.6 billion. The solar installer was founded by his first cousins, Lyndon and Peter Rive, and funded by Musk, who served as board chair. Tesla shareholders later sued, alleging the deal amounted to a SolarCity bailout, and a breach of fiduciary duty that enriched Musk personally. Delaware judges who heard the dispute decided in favor of Musk and Tesla, and allowed the deal to stand without any remuneration back to the automaker.
CoreWeave Inc. signage during the company’s initial public offering at the Nasdaq MarketSite in New York, US, on Friday, March 28, 2025.
Michael Nagle | Bloomberg | Getty Images
It wasn’t supposed to go down like this.
The Trump presidency was set to usher in a rush of money to the markets, spurred by a new era of deregulation and lower taxes that would lead high-valued tech companies off the sidelines and onto public exchanges after a four-year lull in initial public offerings.
Goldman Sachs CEO David Solomon said in January that he sensed a “more constructive kind of optimism” and that the IPO market is “going to pick up.”
But a little over two months into President Donald Trump’s second White House term, the first test case has been a flop.
After downsizing its IPO late Thursday and pricing below its expected range, CoreWeave was unchanged in its market debut on Friday, closing at $40 and leaving the company with a market cap that’s right around where the company was valued by private investors a year ago.
The debut coincided with a 2.7% drop in the Nasdaq on Friday, a decline that put the tech-heavy index down more than 10% in 2025 and on pace ofr its worst quarterly performance since mid-2022.
Macro concerns are being driven by President Trump’s tariffs on America’s top trading partners and dramatic government cost cuts, moves that are combining to simultaneously raise prices and lift unemployment. The deterioration in consumer sentiment was even worse than anticipated in March as worries over inflation intensified, according to a University of Michigan survey released Friday.
That all created a tough backdrop for CoreWeave to try and crack open the IPO market, particularly given concerns swirling around the company and its valuation. CoreWeave is one of the leading suppliers of Nvidia’s graphics processing units, or GPUs, for artificial intelligence training and workloads. Demand has been so hot that CoreWeave’s revenue soared more than 700% last year to almost $2 billion.
However, CoreWeave counts on Microsoft for over 60% of sales and recorded a net loss of $863 million last year, due to the hefty costs of GPUs and the expenses associated with leasing and operating data centers. As of Dec. 31, the company had $8 billion in debt.
“It’s a bit disappointing that the price was dropped so significantly at the open,” Joe Medved, a partner at Lerer Hippeau, told CNBC’s “Money Movers” on Friday. “This company has some idiosyncrasies around debt levels and revenue concentration that I think make it a little challenged.”
The other tech-related companies that have filed to go public this year have very different profiles. Hinge Health is a digital health company that uses software to help patients treat pain and injuries, while Klarna is an online lender and StubHub runs a ticket marketplace.
Those are a few of the names that investors are waiting to see hit the market in the near future, hoping for a rebound after tech IPOs almost ground to a halt in late 2021 and have hardly picked up since. According to CB Insights, there are more than 1,200 startups worldwide worth at least $1 billion in the private market. Over 50 of them have been valued at $10 billion or more.
Despite a dearth of IPOs, the highest-profile startups have been able to raise cash from hedge funds, private equity firms and sovereign wealth funds, which have all jumped into the late-stage venture capital game. Additionally, megacap tech companies including Microsoft, Google, Amazon and Nvidia (one of CoreWeave’s key investors) have poured billions of dollars into private AI companies.
“If you’re the founders or CEOs of these companies, you don’t want to deal with the public markets. There’s plenty of demand from these private buyers,” Medved said. “There’s not as much incentive to go out.”
CoreWeave could be fine. The stock could turn up at any time and the broader market could rebound in the second quarter, lifting investor confidence in IPOs. And CoreWeave has the benefit of roughly $1.5 billion in fresh capital from its share sale, even though that’s well below the $2.7 billion that would’ve been raised at the top end of its range.
But the tepid reception stands in stark contrast to how IPOs looked during the record years of 2020 and 2021, when tech companies would raise the range, price above the top end and still see the stock jump in its debut.
CoreWeave CEO and co-founder Michael Intrator told CNBC’s “Squawk Box” that the pricing of the company’s IPO reflected “a lot of headwinds in the macro.”
“We believe that as the public markets get to know us, get to know how we execute, get to know how we build our infrastructure, get to know how we build our client relationships and the incredible capacity of our solutions, the company will be very successful,” Intrator said.